Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 4/20 | 0.48 |
| ▸ | CYP11B2 | P19099 | 4/20 | 0.48 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.48 |
| ▸ | TRIM24 | O15164 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6605512 | 0.94 | CYP11B1 (0.51) | CYP11B1CYP11B2CYP19A1TRIM24CYP3A4 | |
| SCHEMBL6603785 | 0.92 | ALDH1A1 (0.47) | CYP11B1CYP11B2CYP19A1TRIM24CYP3A4 | |
| SCHEMBL6609493 | 0.86 | CYP11B1 (0.39) | CYP11B1CYP11B2CYP19A1TRIM24CYP3A4 | |
| SCHEMBL6073663 | 0.85 | CYP11B1 (0.51) | CYP11B1CYP11B2CYP19A1TRIM24CYP3A4 | |
| SCHEMBL6606796 | 0.84 | ALDH1A1 (0.45) | CYP11B1CYP11B2CYP19A1TRIM24CYP3A4 | |
| SCHEMBL6605653 | 0.84 | ALDH1A1 (0.45) | CYP11B1CYP11B2CYP19A1TRIM24CYP3A4 | |
| SCHEMBL6073571 | 0.83 | CYP11B2 (0.47) | CYP11B1CYP11B2CYP19A1TRIM24CYP3A4 | |
| SCHEMBL6608644 | 0.83 | CYP11B2 (0.37) | CYP11B1CYP11B2CYP19A1TRIM24CYP3A4 | |
| SCHEMBL6605305 | 0.83 | ALDH1A1 (0.44) | CYP11B1CYP11B2CYP19A1TRIM24CYP3A4 | |
| SCHEMBL6074168 | 0.82 | CYP11B1 (0.40) | CYP11B1CYP11B2CYP19A1TRIM24CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030105124-A1 | Substituted benzolactam compounds | SOBOLOV-JAYNES SUSAN BETH (US) | 2003-06-05 | — | — | US | claimed |
| JP-2002544128-A | — | — | 2002-12-24 | — | — | JP | claimed |
| EP-1175417-A1 | SUBSTITUTED BENZOLACTAM COMPOUNDS | Pfizer Products Inc. (US) | 2002-01-30 | — | — | EP | claimed |
| WO-2000068224-A1 | SUBSTITUTED BENZOLACTAM COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2000-11-16 | — | — | WO | claimed |
| US-8470816-B2 | Nitrogen-containing heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-06-25 | — | — | US | disclosed |
| US-20090156572-A1 | Nitrogen-containing heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2009-06-18 | — | — | US | disclosed |
| US-7119207-B2 | Benzoamide piperidine containing compounds and related compounds | PFIZER INC (US) | 2006-10-10 | — | — | US | disclosed |
| EP-1272484-B1 | BENZOAMIDE PIPERIDINE COMPOUNDS AS SUBSTANCE P ANTAGONISTS | PFIZER PROD INC (US) | 2005-07-20 | — | — | EP | disclosed |
| EP-1175417-B1 | SUBSTITUTED BENZOLACTAM COMPOUNDS | PFIZER PROD INC (US) | 2004-01-07 | — | — | EP | disclosed |
| US-20030105124-A1 | Substituted benzolactam compounds | SOBOLOV-JAYNES SUSAN BETH (US) | 2003-06-05 | — | — | US | disclosed |
| US-20030087925-A1 | Benzoamide piperidine containing compounds and related compounds | PFIZER INC. | 2003-05-08 | — | — | US | disclosed |
| EP-1272484-A2 | BENZOAMIDE PIPERIDINE COMPOUNDS AS SUBSTANCE P ANTAGONISTS | Pfizer Products Inc. (US) | 2003-01-08 | — | — | EP | disclosed |
| EP-1175417-A1 | SUBSTITUTED BENZOLACTAM COMPOUNDS | Pfizer Products Inc. (US) | 2002-01-30 | — | — | EP | disclosed |
| WO-2001077100-A2 | BENZOAMIDE PIPERIDINE COMPOUNDS AS SUBSTANCE P ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2001-10-18 | — | — | WO | disclosed |
| US-6288225-B1 | Substituted benzolactam compounds as substance P antagonists | PFIZER INC | 2001-09-11 | — | — | US | disclosed |
| EP-0840732-B1 | SUBSTITUTED BENZOLACTAM COMPOUNDS AS SUBSTANCE P ANTAGONISTS | PFIZER (US) | 2001-03-07 | — | — | EP | disclosed |
| US-6180647-B1 | GASTROINTESTINAL DISORDERS; NERVOUS SYSTEM DISORDERS | PFIZER INC. | 2001-01-30 | — | — | US | disclosed |
| WO-2000068224-A1 | SUBSTITUTED BENZOLACTAM COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2000-11-16 | — | — | WO | disclosed |
| EP-0840732-A1 | SUBSTITUTED BENZOLACTAM COMPOUNDS AS SUBSTANCE P ANTAGONISTS | PFIZER INC. (US) | 1998-05-13 | — | — | EP | disclosed |
| WO-1997003066-A1 | SUBSTITUTED BENZOLACTAM COMPOUNDS AS SUBSTANCE P ANTAGONISTS | PFIZER PHARMACEUTICALS INC. (JP) | 1997-01-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105124-A1 | Substituted benzolactam compounds | NPY1R, HAX1, CBR1 | CYP11B1 510/4885CYP11B2 487/4885CYP19A1 1658/4885 |
| US-20030087925-A1 | Benzoamide piperidine containing compounds and related compounds | TACR1, VIPR1, VIPR2 | CYP11B1 2904/4885CYP11B2 3109/4885CYP19A1 918/4885 |
| US-20090156572-A1 | Nitrogen-containing heterocyclic compound and use thereof | NTSR2, NTSR1, HNMT | CYP11B1 528/4885CYP11B2 359/4885CYP19A1 1200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.